ROCKVILLE, Md., Aug. 8, 2024
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it
will participate in the H.C. Wainwright 4th Annual
Ophthalmology Virtual Conference on Thursday, August 15, 2024.
H.C. Wainwright 4th Annual Ophthalmology Virtual
Conference
Panel: The Evolving Therapeutic Landscape
of AMD
Date/Time: Thursday, August 15,
2024 at 9:00 a.m. EDT
Location: Virtual
A live webcast of the panel can be accessed in the Investors
section of REGENXBIO's website at www.regenxbio.com. An archived
replay of the webcast will be available for approximately 30 days
following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. Since its founding in 2009, REGENXBIO has pioneered the
development of AAV Therapeutics, an innovative class of gene
therapy medicines. REGENXBIO is advancing a pipeline of AAV
Therapeutics for retinal and rare diseases, including ABBV-RGX-314
for the treatment of wet AMD and diabetic retinopathy, being
developed in collaboration with AbbVie, RGX-202 for the treatment
of Duchenne and RGX-121 for the treatment of MPS II. Thousands of
patients have been treated with REGENXBIO's AAV Therapeutic
platform, including Novartis' ZOLGENSMA® for children with spinal
muscular atrophy. Designed to be one-time treatments, AAV
Therapeutics have the potential to change the way healthcare is
delivered for millions of people. For more information, please
visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-the-hc-wainwright-4th-annual-ophthalmology-virtual-conference-302217608.html
SOURCE REGENXBIO Inc.
